相关实验视频

Updated: Jul 5, 2025

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

在使用治疗所需数量 (NNT) 的治疗耐药抑郁症中,psilocybin和esketamine之间的比较:系统性审查

Sabrina Wong¹, Angela T H Kwan², Kayla M Teopiz³

¹Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

Journal of affective disorders

|January 20, 2024

概括

埃斯凯特胺和 псилоцибин在治疗耐药性抑郁症 (TRD) 中具有临床意义. 这两种治疗都具有可接受的安全性,需要治疗的数量 (NNT) 估计表明TRD成人的有效性.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
药理学药理学是指药理学的学科.

背景情况:

基于单胺的抑郁症治疗方法往往产生不充分的结果,需要新的治疗方法.
耐治疗抑郁症 (TRD) 是一个重大的临床挑战,有效的药理选择有限.
埃斯凯特胺是一种已批准的治疗方法,而 псилоцибин则是TRD的研究药物.

研究的目的:

评估ESKETAMINE和psilocybin在TRD成年人的临床意义.
为了比较TRD患者中需要治疗的数量 (NNT) 和需要伤害的数量 (NNH) 的乙胺和西.

主要方法:

进行了随机对照试验的系统审查.
该综述比较了口服思洛西宾与TRD成年人的口服抗抑郁药相结合的鼻内素的疗效.

主要成果:

松素 (25毫克) 在21天后显著减少了抑郁症状 (NNT=5),恶心是显著的副作用 (NNH=5).
乙胺 (56毫克和84毫克) 在28天后显示出显著的效果 (NNT=7两剂),副作用包括头痛,恶心,头和解离 (NNH <10).

结论:

对psilocybin和esketamine的NNT估计表明在治疗TRD的成年人中具有临床意义.
这两种药物的NNH概况被认为是临床上可接受的.
这些发现凸显了psilocybin和esketamine作为TRD治疗选择的临床相关性.

关键词:

艾斯凯特胺是什么意思治疗所需的数量.这种药物是psilocybin.治疗耐药性抑郁症的治疗方法

更多相关视频

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

相关概念视频

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...